Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Mark Yarchoan, M.D.

Headshot of Mark Yarchoan
  • Assistant Professor of Oncology


Cholangiocarcinoma, Gastrointestinal Cancers, Hepatobiliary Malignancies, Hepatocellular Cancer, Liver Cancer more

Request an Appointment

Insurance Information

Maryland Phone


Outside of Maryland

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8974

The Bunting Blaustein Cancer Research Building

Appointment Phone: 410-955-8964
1650 Orleans Street
Baltimore, MD 21287 map


Dr. Mark Yarchoan is an oncologist in Baltimore, caring for patients with gastrointestinal cancers. His clinical focus is on cancers of the liver, including hepatocellular carcinoma, biliary tract cancers, and fibrolamellar hepatocellular carcinoma.

Dr. Yarchoan received his undergraduate degree (cum laude) in neuroscience from Amherst College and earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Yarchoan joined the Johns Hopkins faculty in 2018.

He directs laboratory research focused on the discovery of novel cancer immunotherapies for hepatobiliary cancers.

Dr. Yarchoan co-leads the Liver Cancer Multidisciplinary Clinic. He has been recognized with an ASCO Young Investigator Award, and the Director’s Teaching Award in Clinical Science. more



  • MD; University of Pennsylvania School of Medicine (2012)


  • Internal Medicine; Hospital of the University of Pennsylvania (2015)


  • Medical Oncology; Johns Hopkins University School of Medicine (2018)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2015)
  • American Board of Internal Medicine (Medical Oncology) (2017)

Research & Publications

Clinical Trial Keywords

Hepatocellular Carcinoma (HCC); Biliary tract cancer (BTC); Cholangiocarcinoma; Liver Cancer; Immunotherapy; Fibrolamellar hepatocellular carcinoma (FLC)

Clinical Trials

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Pancreatic Cancer

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma (FLC)

Selected Publications

View all on PubMed

Yarchoan M, Cope L, Anders RA, Noonan A, Goff LW, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, Davis SL, McRee A, Kunk P, Zhu Q, Wang-Gillam A, Poklepovic A, Chen H, Sharon E, Lesinski GB, Azad N. A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. AACR Annual Meeting Oral Plenary April 2020

Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM. Effects of B cell–activating factor on tumor immunity. JCI Insight. JCI Insight; 2020 May 21;5(10)

Yarchoan M, Huang C, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, Rodriguez C, Osipov A, De Jesus‐Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS (2020) A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med 9: 1485–1494, doi:10.1002/cam4.2763

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM. “PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.” JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377: 2500–2501. PMCID: PMC6549688

Activities & Honors


  • Director’s Teaching Award in Clinical Science, 2019
  • Incyte Young Investigator Award for Translational Science, 2019
  • Young Investigator Award, American Society for Clinical Oncology, 2017
  • ASCO Young Investigator Award, Conquer Cancer Foundation, 2017
  • Inaugural Linda Rubin Fellowship Recipient, Johns Hopkins, 2017
  • Selected Participant, American Association for Cancer Research/American Society for Clinical Oncology Workshop Methods in Clinical Cancer Research, 2016
  • Maurice F. Attie Senior Resident Teaching Award, Hospital of the University of Pennsylvania, 2015
  • Maurice F. Attie Junior Resident Teaching Award, Hospital of the University of Pennsylvania, 2014

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button